Published in Obesity and Diabetes Week, October 25th, 2004
Under terms of the agreement, HaptoGuard obtains exclusive worldwide rights to develop, manufacture and market BXT-51072 and related compounds from a specific OXIS library of antioxidant compounds.
HaptoGuard will be responsible for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week